VANCOMYCIN HYDROCHLORIDE

Post-LOE

vancomycin hydrochloride

Hikma

ANDAINTRAVENOUSPOWDER2 Generics Approved

Approved

Jun 2023

Lifecycle

Post-LOE

Competitive Pressure

60/100

Data completeness

3/8 — Basic

VANCOMYCIN HYDROCHLORIDE (vancomycin hydrochloride) by Hikma is 12. Approved for older) for the treatment of: septicemia () infective endocarditis () skin, skin structure infections () bone infections () lower respiratory tract infections () to reduce the development of drug-resistant bacteria, maintain the effectiveness of vancomycin hydrochloride for injection and 16 more indications. First approved in 2023.

Drug data last refreshed 19h ago

Mechanism of Action

12.1 Mechanism of Action Vancomycin is an antibacterial drug [see ] . 12.2 Pharmacodynamics The pharmacodynamics of vancomycin is unknown. 12.3 Pharmacokinetics In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean…

Worked on VANCOMYCIN HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

VANCOMYCIN HYDROCHLORIDE

Mechanism of Action

Indications (19)